Park National Corp OH lessened its stake in shares of Baxter International Inc (NYSE:BAX) by 5.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,440 shares of the medical instruments supplier’s stock after selling 500 shares during the period. Park National Corp OH’s holdings in Baxter International were worth $768,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of BAX. Gantzert Investment Co. LLC ADV purchased a new stake in Baxter International during the 4th quarter valued at $25,000. Parisi Gray Wealth Management purchased a new stake in Baxter International during the 4th quarter valued at $26,000. Sontag Advisory LLC purchased a new stake in Baxter International during the 4th quarter valued at $30,000. Baldwin Brothers Inc. MA boosted its stake in Baxter International by 904.0% during the 4th quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 452 shares during the last quarter. Finally, We Are One Seven LLC purchased a new stake in Baxter International during the 4th quarter valued at $34,000. 86.17% of the stock is owned by institutional investors.
Several analysts have commented on BAX shares. Zacks Investment Research downgraded Baxter International from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. Morgan Stanley increased their target price on Baxter International from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, March 5th. Piper Jaffray Companies reiterated an “overweight” rating and set a $80.00 target price on shares of Baxter International in a research note on Friday, February 1st. Wells Fargo & Co increased their target price on Baxter International from $72.00 to $76.00 and gave the company an “outperform” rating in a research note on Tuesday, December 4th. Finally, Barclays upgraded Baxter International from an “underweight” rating to an “equal weight” rating and increased their target price for the company from $67.00 to $72.00 in a research note on Friday, February 1st. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $77.31.
Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.05. The firm had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. On average, equities research analysts expect that Baxter International Inc will post 3.27 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were paid a $0.19 dividend. The ex-dividend date of this dividend was Thursday, February 28th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.93%. Baxter International’s dividend payout ratio (DPR) is currently 24.92%.
In related news, Director Thomas T. Stallkamp sold 1,638 shares of Baxter International stock in a transaction on Friday, February 1st. The stock was sold at an average price of $73.75, for a total transaction of $120,802.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Giuseppe Accogli sold 38,297 shares of Baxter International stock in a transaction on Monday, March 18th. The shares were sold at an average price of $76.78, for a total value of $2,940,443.66. Following the transaction, the senior vice president now owns 70,001 shares in the company, valued at $5,374,676.78. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,896 shares of company stock worth $6,157,104. Company insiders own 0.07% of the company’s stock.
About Baxter International
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.